This dual influence creates a feed-forward loop of mineral metabolism imbalance, vascular dysfunction and accelerated CKD progression, underscoring the therapeutic potential of targeting the Klotho-LCN2-FGF23 axis in CKM. Here, LCN2 is linked to chronic kidney disease.